2021 Fiscal Year Final Research Report
Stratification of hardly classifiable brain tumors by combining detailed pathological and genetic analysis
| Project/Area Number |
19K07411
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
Yokoo Hideaki 群馬大学, 大学院医学系研究科, 教授 (40282389)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
信澤 純人 群馬大学, 大学院医学系研究科, 准教授 (80635318)
松村 望 群馬大学, 大学院医学系研究科, 講師 (20729511)
伊古田 勇人 群馬大学, 医学部附属病院, 准教授 (90420116)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 人体病理学 / 分子病理学 / 神経病理学 / 脳腫瘍 |
|---|
| Outline of Final Research Achievements |
It is a social requirement of the current era to refine the pathological diagnosis of brain tumors based on molecular genetic findings and to appropriately stratify individual cases, and pathology that is in a position to bridge the basics and clinical practice should play a big role regarding this. The applicants have established a technique for performing genome-wide analysis from a limited size of formalin-fixed paraffin-embedded (FFPE) sections, and have conducted basic research on divergent brain tumors. In this application, we shed light on difficult-to-classify or rare brain tumors, extracted relevant cases from a huge number of cumulative brain tumor samples, and added molecular genetic profiling to clarify the outline and biological characteristics of the tumor concept. On the other hand, at present, there are some cases where proper stratification is difficult, and we proposed the concept of a framework for properly handling such cases.
|
| Free Research Field |
人体病理学
|
| Academic Significance and Societal Importance of the Research Achievements |
広く海外を見渡すと、地域単位、国単位、あるいは国際間で脳腫瘍研究に関する多施設連携プロジェクトが展開されており、申請者はこの研究課題を本邦を代表する脳腫瘍の研究プロジェクトに発展させる責務があると考えて取り組んできた。申請者の所属施設は半世紀にわたり脳腫瘍症例の収集を続けており、研究規模、研究戦略、研究成果は海外勢と比較しても決して引けを取らない水準にある。これをさらに推し進めて、累積希少症例の遺伝子データマイニングと高精細な病理診断を融合させ、我が国を代表する脳腫瘍の研究拠点形成を目指すという当初の目的はある程度達成できたと考える。引き続き発展を目指してまいりたい。
|
